The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Amplitude of the Late Positive Potential (LPP) in microvolts in response to visual stimuli on the Picture Viewing Task.
Timeframe: End of Treatment (Week 15)
Intensity of demand as assessed by the amount of cocaine purchased and consumed as assessed by cocaine purchasing task
Timeframe: End of Treatment (Week 15)
Cocaine craving as assessed by the score on the Cocaine Cravings Questionnaire
Timeframe: End of Treatment (Week 15)
Proportion of cocaine negative urine drug screens (UDS) during the final two weeks of treatment
Timeframe: From Week 13 to Week 14